ResultsIQ

ResultsIQ › Latest results › Dhampur Bio Organics Limited

Dhampur Bio Organics Limited Q3 FY26 results deck summary

NSE: DBOL · BSE: 543593

Results deck of 22 Jan 2026, summarised by AI from the filing.

No forward guidance was given in the presentation.

Key takeaways

  1. Guidance No forward guidance was given in the presentation.
  2. Change Sugar EBIT margin rose to 11.26% in Q3FY26 from 3.11% in Q3FY25, 815 bps.
  3. Driver Profitability was positively impacted due to higher margins in Sugar.
  4. Risk Revenue declined mainly on lower sugar sales quantity.

Original filing on BSE

Dhampur Bio Organics Limited Q1 FY27 results

As filed: Revenue ₹919 cr (+17% year on year), EBITDA ₹8.9 cr (+300% year on year), PAT ₹36.8 cr, EBITDA margin 1.0% (+85 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹774 cr (+10% year on year), EBITDA ₹94.9 cr (−1% year on year), PAT ₹46.3 cr (+3% year on year), EBITDA margin 12.3% (−139 bps). Score 43 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend. EBITDA margin fell 139 bps year on year. Tax rate 35%. Share price after the results: +6.1% in 30 days (Nifty 500: +1.5%).
  • Q3 FY26: Revenue ₹751 cr (+4% year on year), EBITDA ₹42.6 cr (+151% year on year), PAT ₹16.9 cr, EBITDA margin 5.7% (+331 bps). Score 61 of 100, In line with trend. Revenue growth was in line with the company's own trend; EBITDA growth was well above it. EBITDA margin rose 331 bps year on year. Other income 35% of PBT. Revenue fell 9% from last quarter. Share price after the results: +22.5% in 30 days (Nifty 500: +2.5%).
  • Q2 FY26: Revenue ₹825 cr (+30% year on year), EBITDA −₹7.0 cr, PAT −₹16.0 cr, EBITDA margin -0.9% (+57 bps). Score 45 of 100, In line with trend. Revenue growth was above the company's own trend. EBITDA margin rose 57 bps year on year. Share price after the results: +8.0% in 29 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹784 cr (+23% year on year), EBITDA ₹1.0 cr (−97% year on year), PAT −₹22.0 cr, EBITDA margin 0.1% (−504 bps). Score 15 of 100, Below trend. Revenue growth was above the company's own trend; EBITDA growth was well below it. EBITDA margin fell 504 bps year on year. Profit fell 149% from last quarter. Share price after the results: −3.8% in 29 days (Nifty 500: −1.1%).
  • Q4 FY25: Revenue ₹703 cr (+18% year on year), EBITDA ₹96.0 cr (+19% year on year), PAT ₹45.0 cr (+15% year on year), EBITDA margin 13.7% (+4 bps). Score 59 of 100, In line with trend. Revenue growth was above the company's own trend; EBITDA growth was in line with it. EBITDA margin was flat year on year. Share price after the results: +7.9% in 28 days (Nifty 500: +3.5%).
  • Q3 FY25: Revenue ₹719 cr (+69% year on year), EBITDA ₹17.0 cr, PAT −₹7.0 cr, EBITDA margin 2.4% (+331 bps). Score 15 of 100, Below trend. Revenue growth was well above the company's own trend. EBITDA margin rose 331 bps year on year.
  • Q2 FY25: Revenue ₹634 cr (−5% year on year), EBITDA −₹9.0 cr (−150% year on year), PAT −₹23.0 cr, EBITDA margin -1.4% (−412 bps). Score 10 of 100, Below trend. EBITDA margin fell 412 bps year on year. Not enough history for a trend yet: scored on growth alone.

Past price moves after results do not indicate future moves. Not a recommendation.

Dhampur Bio Organics Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.